Negative antinuclear antibody does not indicate autoantibody negativity in myositis: Role of anticytoplasmic antibody as a screening test for antisynthetase syndrome

Journal of Rheumatology

Volumn 44, Issue 2, 2017, Pages 223-229

  Aggarwal, Rohit ^a   Dhillon, Namrata ^a   Fertig, Noreen ^a   Koontz, Diane ^a   Qi, Zengbiao ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antisynthetase autoantibody dermatomyositis cytoplasmic antibody staining; Antisynthetase syndrome polymyositis antinuclear antibody

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CYTOPLASMIC ANTIBODY; JO 1 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTISYNTHETASE SYNDROME; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMYOSITIS; PREDICTIVE VALUE; RHEUMATOID ARTHRITIS; SCLERODERMA; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; MYOSITIS;

ADULT; ANTIBODIES, ANTINUCLEAR; FEMALE; HUMANS; MALE; MYOSITIS; SENSITIVITY AND SPECIFICITY;

EID: 85011708070     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160618     Document Type: Article

References (31)

1. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-Transfer RNA synthetase. Arthritis Rheum 2007;56:1295-303.
2. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-TRNA synthetase) autoantibodies. Rheumatology 2007;46:842-5.
3. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: A new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007;46:1005-8.
4. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmun Rev 2014;13:367-71.
5. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
6. Hirakata M. Autoantibodies to aminoacyl-TRNA synthetases. Internal Med 2005;44:527-8.
7. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010;1184:134-53.
8. Targoff IN. Update on myositis-specific and myositis-Associated autoantibodies. Curr Opin Rheumatol 2000;12:475-81.
9. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-TRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014;73:227-32.
10. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011;41:674-9.
11. Hallowell RW, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: Recent advances. Curr Opin Rheumatol 2014;26:684-9.
12. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 2005;44:1282-6.
13. Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X, Martinez-Gomez X, Majo-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis-Associated lung disease: Analysis of a series of 81 patients. Lupus 2005;14:534-42.
14. Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Resp Med 2009;103:1719-24.
15. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum 2002;47:434-44.
16. Satoh M, Chan EK, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 2007;3:721-38.
17. Hirakata M. Humoral aspects of polymyositis/dermatomyositis. Modern Rheumatol 2000;10:199-206.
18. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: An update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007;19:523-9.
19. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-90.
20. Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol 2002;9:348-51.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
23. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
24. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To-And anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9.
25. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009;36:2547-51.
26. Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology 2016;55:991-9.
27. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009;60:1112-8.
28. Damoiseaux J, von Mühlen CA, Garcia-De La Torre I, Carballo OG, de Melo Cruvinel W, Francescantonio PL, et al. International consensus on ANA patterns (ICAP): The bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights 2016;7:1.
29. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
30. Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology 2015;54:1194-9.
31. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-Associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 2016;68:689-94.